Key facts, as of
As of November 6, 2026, Bristol-Myers Squibb (BMY) trades at $62.14, up 33.3% over the past year. Its 52-week range runs from $45.27 to $68.64; the price is 9.5% below that high. It is 23.7% below its all-time high of $81.44, reached in December 2022. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +75.2%, against +316.3% for the S&P 500 (SPY). It sits 3.3% above its 200-day average of $60.14. Its 30-day volatility is 36.7% annualized, which we rate high risk. It has a trailing P/E of 13.8 and a dividend yield of 4.06%.
Cite: Portfolio Terminal, "Bristol-Myers Squibb (BMY) stock analysis", 2026-11-06. https://portfolio-terminal.com/analyse/bmy
Where it trades today
trading 72% of the way up its 52-week range
How the price has moved
How far it is from its record
Bristol-Myers Squibb (BMY) is 23.7% below its all-time high of $81.44, reached in December 2022. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +75.2%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- BMY closes below its 50-day average ($62.35) while the 50-day is still above the 200-day ($60.14): a pullback inside a longer rise, not yet a downtrend.
- At $62.14, BMY is 9.5% below its 1-year high of $68.64, set on August 19, 2026, and 37.3% above its 1-year low of $45.27 (November 20, 2025).
- Over the past month BMY rose 4.3%, from $59.58 to $62.14.
- BMY trades at 13.8x its last twelve months of earnings and 9.3x the next twelve months' estimate, so analysts expect earnings 48.5% higher.
- Its P/E is 68.6% below the 43.9x median of the 3 other drug manufacturers—general companies we track (LLY, JNJ, ABBV).
- BMY's 30-day volatility, 36.7% a year, works out to a typical daily move of about 2.3%.
- Yahoo Finance puts its beta at 0.19: over five years of monthly returns, BMY moved about 0.19% for each 1% move of the S&P 500.
What would change the read
- A close back above the 50-day average, $62.35 (+0.3%), restores the uptrend; the 50-day falling 3.5% under the 200-day at $60.14 would make it a downtrend.
- A close above $68.64 (+10.5%) would be a new 1-year high; below $45.27 (−27.1%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for BMY, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under drug manufacturers—general among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for BMY by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for BMY. Last refresh: Nov 8, 2026, 10:53 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Drug Manufacturers—General.
What Bristol-Myers Squibb does
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of…
Employees
32,500
Industry
Drug Manufacturers - General
Headquarters
Princeton, United States
What analysts expect
BMY carries a buy consensus from 24 analysts, with an average price target of $65.25 versus $62.14 today (+5.0%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
BMY generated $50.03B in trailing revenue (6.9% year over year), with a 18.5% net margin, and $6.36B of free cash flow, against $32.23B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $48.20B | $34.26B | $13.72B | $7.05B | $3.47 | $12.85B |
| 2024 | $48.30B | $34.33B | $5.89B | -$8.95B | -$4.41 | $13.94B |
| 2023 | $45.01B | $34.31B | $8.20B | $8.03B | $3.88 | $12.65B |
| 2022 | $46.16B | $36.02B | $9.10B | $6.33B | $2.97 | $11.95B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
BMY is in 18 of the 54 ETFs we track. It weighs most in SCHD: 2.92% of the fund, holding #16 of 100.
How its figures compare with those peers
Companies in the same industry
BMY beside the other companies Yahoo Finance files under drug manufacturers—general among the assets we track (LLY, JNJ, ABBV, largest first).
BMYyou are here$62.14$127.02B
LLYEli Lilly and Company$1354.00$1.21T
JNJJohnson & Johnson$276.22$664.95B
ABBVAbbVie Inc.$291.31$514.92BWhat the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 0.3% below its 50-day average and 3.3% above its 200-day.
- RSI at 51 is neither stretched nor washed out.
- The nearest ceiling is $62.75 (+1.0%), the nearest floor $60.42 (-2.8%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is BMY valued right now?
Bristol-Myers Squibb trades at 13.8 times its last twelve months of earnings and 9.3 times the next twelve months' estimate (Yahoo Finance, November 6, 2026). On the chart: slipped under its 50-day average inside a longer uptrend. Price is 0.3% below its 50-day average and 3.3% above its 200-day.
What is the risk level of BMY?
Based on 30-day volatility of 36.7%, BMY has HIGH risk. Its beta of 0.19 means it has swung less than the S&P 500 over the last five years.
Does BMY pay dividends?
Yes, Bristol-Myers Squibb has a dividend yield of 4.06%.
How far is BMY from its all-time high?
Bristol-Myers Squibb is 23.7% below its all-time high of $81.44, reached in December 2022. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +75.2%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold BMY?
18 of the 54 popular ETFs we track hold Bristol-Myers Squibb. The largest weights: SCHD (2.92%), XLV (1.90%), JEPI (0.61%), VYM (0.54%) and VTV (0.48%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is BMY?
0.19%, as of September 30, 2026: BMY is holding #87 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $1.94 in Bristol-Myers Squibb.
What is the analyst price target for BMY?
The average analyst price target for Bristol-Myers Squibb (BMY) is $65.25 based on 24 analyst estimates, about 5.0% above the current price of $62.14. The published range runs from $40.00 to $80.00.
How much revenue does BMY generate?
Bristol-Myers Squibb reported $50.03B in trailing twelve-month revenue. Revenue growth is running at 6.9% year over year. Net margin sits at 18.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare BMY with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.